drugset / Trial / NCT00651079

GSK1247303 First Time in Human Study

NCT00651079 ↗

Phase 1 Terminated 58 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

To determine safety, tolerability and Pharmacokinetics of GSK1247303

Timeline

Start
2008-02
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK1247303 Unknown — —

Indications

No indication recorded.